{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:19:08Z","timestamp":1762017548347,"version":"3.37.3"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1124\/jpet.111.187906","type":"journal-article","created":{"date-parts":[[2011,11,3]],"date-time":"2011-11-03T03:18:37Z","timestamp":1320290317000},"page":"369-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antiserotonergic Properties of Terguride in Blood Vessels, Platelets, and Valvular Interstitial Cells"],"prefix":"10.1016","volume":"340","author":[{"given":"Alexandra","family":"Kekewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilo","family":"G\u00f6rnemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Jantschak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Glusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz H.","family":"Pertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.111.187906_bib1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1474-4422(09)70225-X","article-title":"A reassessment of risks and benefits of dopamine agonists in Parkinson\u2019s disease","volume":"8","author":"Antonini","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1124\/jpet.111.187906_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0022-3565(25)23410-3","article-title":"Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation","volume":"249","author":"Bond","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187906_bib3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0028-3908(97)00049-X","article-title":"RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist","volume":"36","author":"Bonhaus","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.187906_bib4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1183\/09031936.96.09020356","article-title":"The role of thrombosis in severe pulmonary hypertension","volume":"9","author":"Chaouat","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.111.187906_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1172\/JCI20729","article-title":"Disorders of lung matrix remodeling","volume":"113","author":"Chapman","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.111.187906_bib6","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2353\/ajpath.2009.081101","article-title":"Fenfluramine disrupts the mitral valve interstitial cell response to serotonin","volume":"175","author":"Connolly","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.111.187906_bib7","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.20101629","article-title":"Platelet-derived serotonin links vascular disease and tissue fibrosis","volume":"208","author":"Dees","year":"2011","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.111.187906_bib8","doi-asserted-by":"crossref","first-page":"H1940","DOI":"10.1152\/ajpheart.01177.2008","article-title":"Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study","volume":"296","author":"Droogmans","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/jpet.111.187906_bib9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1183\/09031936.00126010","article-title":"Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats","volume":"37","author":"Dumitrascu","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.111.187906_bib10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1183\/09031936.00126907","article-title":"Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice","volume":"32","author":"Fabre","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.111.187906_bib11","first-page":"215","article-title":"Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents","volume":"43","author":"Glusa","year":"1984","journal-title":"Biomed Biochim Acta"},{"key":"10.1124\/jpet.111.187906_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/sj.bjp.0703341","article-title":"Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT2B receptors","volume":"130","author":"Glusa","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.111.187906_bib13","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1124\/jpet.107.133165","article-title":"Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-hydroxytryptamine 2B and 5-hydroxytryptamine 2A receptors","volume":"324","author":"G\u00f6rnemann","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187906_bib14","doi-asserted-by":"crossref","first-page":"F922","DOI":"10.1152\/ajprenal.1999.276.6.F922","article-title":"Serotonin 5-HT2A receptor induces TGF-\u03b21 expression in mesangial cells via ERK: proliferative and fibrotic signals","volume":"276","author":"Grewal","year":"1999","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.111.187906_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.regpep.2007.02.009","article-title":"Long-term serotonin effects in the rat are prevented by terguride","volume":"143","author":"Hauso","year":"2007","journal-title":"Regul Pept"},{"key":"10.1124\/jpet.111.187906_bib16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease\u2013it was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.111.187906_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejphar.2005.03.010","article-title":"Agonism at 5-HT2B receptors is not a class effect of the ergolines","volume":"513","author":"J\u00e4hnichen","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.187906_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.111.181255","article-title":"The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease","volume":"338","author":"Kekewska","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 3","key":"10.1124\/jpet.111.187906_bib19","first-page":"101","article-title":"Ketanserin prevents early restenosis following percutaneous transluminal coronary angioplasty","volume":"8","author":"Klein","year":"1990","journal-title":"Clin Physiol Biochem"},{"key":"10.1124\/jpet.111.187906_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00210-008-0378-4","article-title":"Pharmacological characterization of mitogen-activated protein kinase activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors","volume":"379","author":"Knauer","year":"2009","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.111.187906_bib21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/thx.2009.134353","article-title":"Increased expression of 5-hydroxytryptamine 2A\/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention","volume":"65","author":"K\u00f6nigshoff","year":"2010","journal-title":"Thorax"},{"key":"10.1124\/jpet.111.187906_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.33549\/physiolres.930402","article-title":"Pergolide, terguride and N,N\u2032-spacer-linked oligomers of both interact with 5-HT2A receptors of rat tail artery","volume":"53","author":"Kren","year":"2004","journal-title":"Physiol Res"},{"key":"10.1124\/jpet.111.187906_bib23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nm764","article-title":"Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension","volume":"8","author":"Launay","year":"2002","journal-title":"Nat Med"},{"key":"10.1124\/jpet.111.187906_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCULATIONAHA.105.554667","article-title":"Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice","volume":"113","author":"Mekontso-Dessap","year":"2006","journal-title":"Circulation"},{"key":"10.1124\/jpet.111.187906_bib25","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0022-3565(25)38269-8","article-title":"Species differences in the pharmacology of the 5-hydroxytryptamine 2 receptor: structurally specific differentiation by ergolines and tryptamines","volume":"265","author":"Nelson","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187906_bib26","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/jpet.102.039875","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and \u03b11\/\u03b12-adrenoceptor","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187906_bib27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187906_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1538-7836.2005.01702.x","article-title":"Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery","volume":"4","author":"Nishihira","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1124\/jpet.111.187906_bib29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/BF00176616","article-title":"O-acylated lysergol and dihydrolysergol-I derivatives as competitive antagonists of 5-HT at 5-HT2 receptors of rat tail artery. Allosteric modulation instead of pseudoirreversible inhibition","volume":"345","author":"Pertz","year":"1992","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.111.187906_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.111.187906_bib31","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1124\/jpet.111.187906_bib32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2353\/ajpath.2006.050767","article-title":"A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis","volume":"169","author":"Ruddell","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.111.187906_bib33","series-title":"Psychopharmacology: The Fourth Generation of Progress","first-page":"431","article-title":"Serotonin receptors. Signal transduction pathways","author":"Sanders-Bush","year":"1995"},{"key":"10.1124\/jpet.111.187906_bib34","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","article-title":"3,4-Methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro","volume":"63","author":"Setola","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.187906_bib35","doi-asserted-by":"crossref","first-page":"195S","DOI":"10.1378\/chest.114.3_Supplement.195S","article-title":"Primary pulmonary hypertension associated with the use of fenfluramine derivatives","volume":"114","author":"Simonneau","year":"1998","journal-title":"Chest"},{"key":"10.1124\/jpet.111.187906_bib36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1017\/S1092852900024020","article-title":"Mechanism of action of trazodone: a multifunctional drug","volume":"14","author":"Stahl","year":"2009","journal-title":"CNS Spectr"},{"key":"10.1124\/jpet.111.187906_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0002-9440(10)64529-4","article-title":"The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system","volume":"157","author":"Swaisgood","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.111.187906_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0014-5793(95)00828-W","article-title":"Expression of serotonin receptor mRNAs in blood vessels","volume":"370","author":"Ullmer","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.111.187906_bib39","first-page":"299","article-title":"Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters","volume":"143","author":"Van Rossum","year":"1963","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1124\/jpet.111.187906_bib40","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/S0002-9440(10)64497-5","article-title":"Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells","volume":"161","author":"Xu","year":"2002","journal-title":"Am J Pathol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652446727X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652446727X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.111.187906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:41:56Z","timestamp":1740019316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652446727X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S002235652446727X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.111.187906","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiserotonergic Properties of Terguride in Blood Vessels, Platelets, and Valvular Interstitial Cells","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.111.187906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}